Block & Leviton LLP Announces Securities Fraud Investigation Of Ocular Therapeutix, Inc. (OCUL) And Encourages Shareholders To Contact The Firm

BOSTON, July 8, 2017 /PRNewswire/ -- Block & Leviton LLP (www.blockesq.com), a securities litigation firm representing investors nationwide, is investigating whether Ocular Therapeutix, Inc. ("Ocular" or the "Company") (NASDAQ: OCUL) and certain of its officers and directors violated federal securities laws.

On Jul 6, 2017, near the close of trading, the investor website Seeking Alpha published an article entitled "Ocular: A Poke In The Eye," reporting that Ocular is on "the brink of collapse" and that they may be "misleading investors" about ongoing manufacturing issues and the Company's communications with the FDA about those issues.

On this news, Ocular's stock has fallen more than 30% to close at $7.12 on July 7, 2017, causing tens of millions in losses to shareholders.

If you purchased or otherwise acquired Ocular securities and have questions about your legal rights or possess information relevant to this investigation, please contact attorney Bradley Vettraino at (617) 398-5600, by email at [email protected], or by visiting www.blockesq.com/ocular.  

Confidentiality to whistleblowers or others with information relevant to this investigation is assured.

Block & Leviton LLP is a Boston-based law firm representing investors nationwide. The firm's lawyers have collectively been prosecuting securities cases on behalf of individual and institutional investors for over 50 years, and have recovered billions of dollars on their behalf. Block & Leviton's investigations into corporate wrongdoing were recently covered by the New York Times.

This notice may constitute attorney advertising.

CONTACT:

Block & Leviton LLP
Bradley J. Vettraino
155 Federal Street, Suite 400
Boston, MA 02110
(617) 398-5600
[email protected]

SOURCE Block & Leviton LLP

Related Links

http://www.blockesq.com